Meeting
2020 Genitourinary Cancers Symposium
ABLE: single-arm trial of nab-paclitaxel with ANTI-PD1 in advanced urothelial cancer.
Authors
Jason Brown
Department of Internal Medicine, University of Michigan, Ann Arbor, MI
Jason Brown , Stephanie Daignault , Zachery R. Reichert , Phillip Lee Palmbos , Ajjai Shivaram Alva
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03240016
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 520)
Abstract #
520
Poster Bd #
K1
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— Updated response and survival results.
First Author: Peter H. O'Donnell
Poster
2021 Gastrointestinal Cancers Symposium
Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.
First Author: Josep Tabernero
Poster
2019 ASCO Annual Meeting
KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC).
First Author: Jae-Lyun Lee
Poster
2019 ASCO Annual Meeting
Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.
First Author: Yung-Jue Bang